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Photochemical Properties and Structure–Activity Relationships 
of RuII Complexes with Pyridylbenzazole Ligands as Promising 
Anticancer Agents
Dmytro Havrylyuk, David K. Heidary, Leona Nease, Sean Parkin, and Edith C. Glazera
aDepartment of Chemistry, University of Kentucky, 505 Rose Street, Lexington, Kentucky 40506, 
United States
Abstract
Ruthenium complexes capable of light-triggered cytotoxicity are appealing potential prodrugs for 
photodynamic therapy (PDT) and photoactivated chemotherapy (PACT). Two groups of Ru(II) 
polypyridyl complexes with 2-(2-pyridyl)-benzazole ligands were synthesized and investigated for 
their photochemical properties and anticancer activity to compare strained and unstrained systems 
that are likely to have different biological mechanisms of action. The structure-activity relationship 
was focused on the benzazole core bioisosterism and replacement of coligands in Ru(II) 
complexes. Strained compounds rapidly ejected the 2-(2-pyridyl)-benzazole ligand after light 
irradiation, and possessed strong toxicity in the HL-60 cell line both under dark and light 
conditions. In contrast, unstrained Ru(II) complexes were non-toxic in the absence of light, 
induced cytotoxicity at nanomolar concentrations after light irradiation, and are capable of light-
induced DNA damage. The 90−220-fold difference in light and dark IC50 values provides a large 
potential therapeutic window to allow for selective targeting of cells by exposure to light.
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Introduction
Cancer is currently the second leading cause of death in the United States, following heart 
disease. More than 1.7 million people are estimated to be diagnosed with cancer in 2016.[1] 
With global cancer morbidity rising, the development of new cancer treatments is crucial. 
Chemotherapy is used in most treatment regimens for cancer. Since its discovery in the late 
1960s, cisplatin and derivatives thereof have achieved great success, and nearly 50% of 
patients being treated for cancer are given a platinum based drug.[2] Widespread treatment 
with cisplatin, however, revealed major clinical problems associated with its use. Cisplatin 
has dose-limiting side effects, such as nephrotoxicity, neurotoxicity, ototoxicity, and 
myelosuppression.[3] Due to these severe side effects, cisplatin has to be administered at 
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concentrations that might not be lethal to tumor cells, thereby facilitating development of 
drug resistance. These limitations have driven the investigations of other (non-platinum) 
transition metal compounds.
In recent years, ruthenium-based complexes have emerged as promising antitumor and 
antimetastatic agents with potential uses in platinum-resistant tumors.[4] Ruthenium 
compounds are well suited for medical applications due to a combination of chemical and 
biological properties: they can form multiple geometries with facile ligand exchange, they 
can be activated by environmental features or external triggers, and they are capable of 
mimicking iron binding for transportation.[5] The different oxidation states can be exploited 
to design prodrugs, where the inactive 3+ ruthenium complexes can be reduced to 2+, 
creating an active species and a biological effect. The reducing environment of tumors has 
been associated with the selective activity of ruthenium-based drugs NAMI-A, KP1019, and 
KP1339, which have been investigated in clinical trials.[6] An alternative prodrug strategy is 
to use light to transform inert complexes into cytotoxic agents.[7] We have demonstrated that 
this can be accomplished with strained Ru(II) polypyridyl complexes with distorted 
octahedral geometry, which photo-decompose via ligand dissociation.[8] The resulting 
ligand-deficient Ru(II) center can covalently modify DNA or other biomolecules, and induce 
cytotoxicity.[9]
The application of light-mediated ruthenium complexes can be divided into two categories: 
photodynamic therapy (PDT) and photoactivated chemotherapy (PACT).[10] PDT relies 
mainly on the generation of the toxic reactive oxygen species (ROS) such as singlet oxygen 
(1O2). In contrast, PACT exploits different mechanisms to induce cell death, such as ligand 
ejection to create metal centers able to form DNA adducts, or photocaging approaches. In 
this article, we present the investigation of strained and unstrained ruthenium (II) complexes 
with 2-(2-pyridyl)-benzazole ligands as promising antitumor agents with possible 
application in both PDT and PACT.
The benzazole moiety was chosen as it combines features including extended conjugation 
for modulation of the absorption profile, and the potential for intrinsic steric clash within a 
coordination complex, similar to quinoline-containing ligands.[8b] It also facilitated a 
systematic investigation as it provided a single point for chemical variation, with a 
heteroatom (N, O, S) at the 1-position with a nitrogen at the 3-position, or a carbon at the 
analogous position in indole (Scheme 1). Moreover, benzazole-containing systems exhibit a 
variety of biological activities and applications. Recently, organometallic systems containing 
this ligand type have been explored, including half-sandwich ruthenium(II) arene 
compounds with pyridyl-benzimidazole ligands studied for their DNA binding ability,[11] 
cyclin-dependent kinase (CDK1) inhibitory effects,[11b] and inhibition of protein tyrosine 
phosphatase (PTP-1B).[12] The previous investigations of ruthenium complexes with aryl-
benzimidazole ligands showed cytotoxic effect at μM concentrations.[11b, 13]
In this report, we have discovered that coordination of non-cytotoxic 2-(2-pyridyl)-
benzazole ligands with a Ru(dmphen)2 (dmphen = 2,9-dimethyl-1,10-phenanthroline) 
scaffold, forming strained Ru(II) complexes, promoted significant cytotoxic potential of 
compounds with single μM IC50 values both in dark and light conditions. In contrast, the 
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complexes with 2,2′-bipyridine (bpy) ligands were not active in the absence of light. 
However, these compounds were effective in killing cells when irradiated, producing nM 
IC50 values. DNA damage analysis and evaluation of singlet oxygen production confirmed 
that unstrained compounds generate toxic ROS. However, the disparity in the effective 
concentration and trends for cytotoxicity (IC50< 1 μM) and singlet oxygen generation (> 10 
μM) suggests that these compounds act through some additional, currently unknown, 
mechanism(s) of action.
Results and Discussion
Synthesis and Characterization
To explore structure-activity relationships (SAR), a small family of heteroleptic Ru(II) 
complexes (5–12) were synthesized that contained one 2-(2-pyridyl)benzazole type ligand 
and two strain-inducing dmphen ligands or two bpy ligands as shown in Scheme 1. Four 
heterocyclic bioisosteres were studied: 2-(2-pyridyl)indole (pi) 1, 2-(2-
pyridyl)benzimidazole (pbi) 2, 2-(2-pyridyl)benzoxazole (pbo) 3 and 2-(2-
pyridyl)benzothiazole (pbt) 4. These systems were chosen in order to investigate the impact 
of replacement of one pyridyl-type ligand with a benzazole on the cytotoxicity and 
photochemical properties of the Ru(II) complexes.
The Ru(II) complexes were synthesized from a racemic mixture of the Δ and Λ enantiomers 
of Ru(dmphen)2Cl2 or Ru(bpy)2Cl2 and thus form a mixture of enantiomers upon 
coordination of the pyridyl-benzazole ligands. All complexes were exhaustively purified to 
ensure no contamination of either free ligands or coordinatively unsaturated Ru(II) centers. 
As the pyridyl-indole is deprotonated, the complexes carry a +1 charge; all other complexes 
are +2 charged. The complexes were characterized by 1H NMR spectroscopy, ESI-MS, X-
ray and UV (see Figure S6–10, S18–27 in the Supporting Information). The strained 
complexes 5–8 were synthesized and characterized for the first time; the unstrained 
complexes 9–12 have been described previously.[14] In contrast to the described 1H NMR 
spectra (300 MHz, CD3CN) for 11 and 12,[14b] we observed that some resonances for H4 
and H5 of bpy coligands were resolved as doublet of doublets of doublets (ddd).[15]
X-ray Crystallography
The structures of complexes 6–8 were determined by X-ray crystallography and are shown 
in Figure 1. Selected bond lengths and angles are listed in Table 1.
As expected, complexes 6–8 exhibited distorted octahedral geometries. Incorporation of two 
dmphen ligands resulted in the Ru−N bond lengthening to 2.108 Å (average value for 6), 
2.103 Å (average value for 7), and 2.105 Å (average value for 8), in comparison with 2.040–
2.059 Å for the corresponding complexes with bpy coligands.[14b, 16] The bond length to the 
pyridine ring (Ru-N5) is shorter in the pbo and pbt ligands than the bond to the benzazole 
ring, while the Ru-N6 bond to the benzimidazole is shorter than to the pyridine ring in 6 
(Table 1). In contrast to complexes containing the 2,2′-biquinoline ligand,[8b] the two ring 
systems in the benzazole-containing ligands are essentially co-planar, and do not contribute 
significantly to the distortion in the complexes.
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The bond angles between dmphen ligands are nonequivalent, with the largest distortion from 
the ideal 90° and 180° for complex 8. These deviations are larger than for unstrained 
compound 11 (Figure S5).[14b] Both the dmphen ligands (L1 and L2, Figure 1, Table 1) for 
each compound 6–8 are considerably bent from the normal plane, with deviations of 19.5–
22.7°. While the bend angle for L1 is the same for all complexes, the bends of L2 are not 
equivalent for 6–8, creating variations in strain in the molecules that could cause the 
difference in photoejection kinetics (Table 2).
Photochemistry
The photochemical reaction of strained Ru(II) complexes 5–9 were monitored by absorption 
spectroscopy, and exhibited selective photoejection of one ligand when irradiated with >450 
nm light, as shown in Figure 2A and Figures S6–10. The presence of an isobestic point 
indicated the direct conversion to a single product (Figure 2A). The half-life (t1/2) of ligand 
ejection in water for 6–8 is 40–140× faster than for 5.
Complex 8 exhibited the fastest ejection, and also the largest bend of dmphen ligand (L2, 
Table 1), indicating a correlation between the strain in the complex and the photochemical 
properties. The half-life was also found to be sensitive to the environment, as compound 6 
demonstrated a 9-fold slower ligand ejection in Opti-MEM, the media used in tissue culture 
experiments, than in water (Table 2).
The selective ejection of the 2-(2-pyridyl)benzazole ligands after irradiation of 6–8 in water 
was confirmed by HPLC by comparison with starting complex and ligands (Figure 2E; the 
same light dose was used as in the cell experiments). Most unstrained Ru(II) complexes with 
bpy coligands (10–12) did not eject after 4 h irradiation, but complex 9 gave a t1/2 of 66 min 
(Table 2).
Cytotoxicity, SAR and DNA Damage
An SAR study was performed for 2-(2-pyridyl)benzazole ligands based on benzazole core 
bioisosterism and the corresponding Ru(II) complexes with dmphen or bpy coligands. None 
of the free ligands exhibited activity against a leukemic cell line (HL60 human 
promyelocytic leukemia) up to 100 μM concentrations (Figure 3, Table 3). Compounds 5–8 
were 20–300-fold more potent against HL60 cell line than parent ligands, with IC50 values 
ranging from 0.34–4.55 μM. Unexpectedly, the photoreactive compounds 6–8 exhibited the 
same range of activity under dark and light conditions. However, the strained Ru(II) 
complexes exhibited a steeper dose response when light activated, and caused essentially 
complete cell death in lower concentrations (Figure 3A).
For the photoejecting systems, the largest Phototoxicity Index (PI) value was found for 
complex 5, which produced a 10-fold enhanced activity upon irradiation, with a 34 nM IC50 
value (Table 3). The highest PI values were found for 10–12, which contain the Ru(bpy)2 
scaffold. After irradiation, compounds 9, 10, and 12 produced submicromolar IC50 values, 
with 7–220-fold differences in the light and dark, and demonstrated 3–17-fold greater 
potencies than cisplatin. The 88-fold (12, Figure S13) and 224-fold (10, Figure 3B) 
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difference in light and dark IC50 values provides a large potential therapeutic window to 
allow for selective targeting of cells by exposure to light.
The SAR study revealed the following: (1) coordination of 2-(2-pyridyl)benzazole ligands 
with the Ru(II) scaffolds is crucial for potency; (2) the cytotoxic effect is sensitive to the 
coligands (dmphen vs bpy) – replacement of dmphen with bpy decreased the potency in the 
dark, but promoted the nM activity after light irradiation (compounds 9, 10, 12) and 
provided a large potential therapeutic window (88 for 12 and >220 for 10); (3) the nature of 
a benzazole core had an influence on the antitumor activity, with complexes 5 and 9 
exhibiting 5–35-fold greater potency under dark conditions in comparison to other 
compounds from strained and unstrained groups, respectively (Table 3, Figure 4). It should 
be noted that complexes 5 and 9 carry a +1 charge, while all other compounds were +2.
The effect of the compounds 8 and 12 on cell cycle was analyzed at the IC50 of the 
compounds over several time points (Figures S15,16). At the 24 h time point, the sub-G1 
phase had increased to 45% of the population for 8 and 27% for 12 when the compounds 
had been irradiated. No significant increase in the population of apoptotic cells and the G1, 
S or G2/M populations occurred for 8 and 12 in the dark. Thus, neither compound induced 
cell cycle arrest under dark conditions or upon irradiation.
In an attempt to determine a potential mechanism of action, DNA damage was assessed by 
agarose gel electrophoresis. Supercoiled pUC19 plasmid was incubated with each complex 
in dose response and kept in the dark or exposed to 470 nm light for one hour (Figure 5). 
The irradiated samples revealed significant differences in damage profiles. The strained 
photoactive Ru(II) complexes 6 and 8 exhibited a combination of DNA photocleavage and 
DNA photobinding (Figure 5A, B). Covalent adducts were visualized by the reduced 
mobility on the agarose gel with increasing concentration of Ru(II) complex, as well as loss 
of EtBr signal. Unstrained complex 12 induced single-strand breaks in the DNA when 
irradiated with light, likely due to the photogeneration of 1O2. This was visualized by the 
conversion from supercoiled DNA to relaxed circle (Figure 5D). Unexpectedly, unstrained 
10 produced fewer single-strand breaks than 12 based on the small ratio between relaxed 
circle and supercoiled DNA (Figure 5C). Precipitation of the DNA with the complexes 5, 8, 
and 9 was observed at concentrations above 125 μM.
Despite the difference in their ability to inflict DNA damage, both the unstrained compounds 
10 and 12 induced submicromolar cytotoxicity after light irradiation and exhibited large PI 
values. In an attempt to confirm or disprove the involvement of light-activated generation 
of 1O2 in the biological mechanism of action, dose responses of compounds were performed 
with Singlet Oxygen Sensor Green reagent with light irradiation (Figure 5E; Figure S15). As 
anticipated, photogeneration of 1O2 was observed for both unstrained complexes 10 and 12, 
in contrast to corresponding strained compounds 6 and 8. Consistent with the DNA damage 
gels, compound 12 exhibited greater potency for 1O2 generation; however, there is a large 
discrepancy between the concentrations needed to produce 1O2 or induce strand breaks in 
the DNA compared to cytotoxicity IC50 values. This suggests that 1O2 alone cannot be 
responsible for the potent effects in cells.[17] Moreover, the pyridyl-indole based complexes 
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(5 and 9) possessed the highest cytotoxicity and did not generate 1O2 upon irradiation 
(Figure S15).
CONCLUSIONS
Eight heteroleptic Ru(II) complexes were synthesized in order to explore structure−activity 
relationships. The complexes contained one 2-(2-pyridyl)benzazole type ligand combined 
with either two dmphen ligands to make intrinsically strained complexes, or two 2,2′-
bipyridine ligands to form unstrained complexes. While the free benzazole type ligands 1–4 
were not toxic in the investigated concentration range, the Ru(II) complexes exhibited 
marked cytotoxicity. The most potent compounds, 5 and 9, contained the 2-(2-pyridyl)indole 
ligand, and were highly effective in killing leukemic cells when irradiated, with IC50 values 
less than 0.04 and 0.2 μM. However, the observed high toxicity in the dark could be a 
limitation for their potential application as PDT agents.
In contrast, large therapeutic windows were found for complexes 12 and 10 (with 88- and 
224-fold differences in light and dark IC50 values), which demonstrated 3–15-fold greater 
potency than cisplatin. The unstrained compounds are capable of generating singlet oxygen, 
but the significant disparity in the effective concentration for cytotoxicity, 1O2 production, 
and DNA cleavage suggests that some other, currently unknown, mechanisms of action 
could be involved for anticancer activity. This may involve different species of ROS.
Considering the promising dark-cytotoxicity of strained complexes and light-induced 
antitumor potential of unstrained compounds, we are currently modifying these complexes, 
aiming to generate more potent anticancer agents with possible application in both standard 
chemotherapy and photodynamic therapy.
EXPERIMENTAL SECTION
Materials and Methods
The starting 2-(2-pyridyl)benzazole ligands were obtained from commercial sources (2,3) or 
were synthesized according to the methods described previously (1,4).[18] Complexes 10–12 
were synthesized using previously established procedures.[14]
All 1H NMR spectra were obtained on a Varian Mercury spectrometer (400 MHz) with 
chemical shifts reported relative to the residual solvent peak of acetonitrile at δ 1.94. 
Electrospray ionization mass spectra were obtained on a Varian 1200L mass spectrometer. 
Absorption spectra were obtained on an Agilent Cary 60 spectrophotometer or a BMG 
Labtech FLUOstar Omega microplate reader. Photoejection, DNA damage, and singlet 
oxygen generation experiments were performed using a 470 nm LED array from Elixa, and 
a Loctite Indigo LED array (for cell cytotoxicity studies and HPLC photoejection analysis). 
All synthesized compounds were isolated in >95% purity, as determined by analytical 
HPLC. For HPLC analysis, the ruthenium complexes were injected on an Agilent 1100 
series HPLC equipped with a model G1311 quaternary pump, G1315B UV diode array 
detector, and ChemStation software version B.01.03. Chromatographic conditions were 
optimized on a Column Technologies Inc. C18, 120 Å (250 mm × 4.6 mm inner diameter, 5 
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μM) fitted with a Phenomenex C18 (4 mm × 3 mm) guard column. Injection volumes of 15 
μL of 100 μM solutions of the complex were used. The detection wavelength was 280 nm. 
Mobile phases were: mobile phase A, 0.1% formic acid in dH2O; mobile phase B, 0.1% 
formic acid in HPLC grade acetonitrile. The mobile phase flow rate was 1.0 mL/min. The 
following mobile phase gradient was used: 98−95% A (containing 2− 5% B) from 0 to 5 
min; 95−70% A (5−30% B) from 5 to 15 min; 70−40% A (30−60% B) from 15 to 20 min; 
40−5% A (60−95% B) from 20 to 30 min; 5−98% A (95−2% B) from 30 to 35 min; 
reequilibration at 98% A (2% B) from 35 to 40 min.
General procedure for synthesis of Ru(dmphen)2L complexes with 2-(2-pyridyl)benzazole 
ligands
Ru(dmphen)2Cl2 (1 eq) and 2-(2-pyridyl)benzazole (1.1 eq) were added to 4 mL of ethylene 
glycol in a 15 mL pressure tube. The mixture was heated at 100–120 °C for 2 h while 
protected from light. The dark brown (5) or orange solution (6–8) was allowed to cool to 
room temperature and poured into 50 mL of dH2O. Addition of a saturated aq. KPF6 
solution (ca. 1 mL) produced a brown or red-orange precipitate that was collected by 
vacuum filtration. The purification of the solid was carried out by flash chromatography 
(silica gel, loaded in 0.1% KNO3, 5%H2O in MeCN). A gradient was run, and the pure 
complex eluted at 0.2% KNO3, 5–10% H2O in MeCN. The product fractions were 
concentrated under reduced pressure, and a saturated aq solution of KPF6 was added, 
followed by extraction of the complex into CH2Cl2. The solvent was removed under reduced 
pressure to give a solid.
5 Rf=0.63 (0.1% KNO3, 5%H2O in MeCN); 1H NMR (CD3CN): δ 8.59 (d, J = 8.2 Hz, 1H), 
8.52 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 8.3 Hz, 1H), 816 (d, J = 8.7 Hz, 1H), 8.02–8.06 (m, 
3H), 7.81 (d, J = 8.7 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 
8.3 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 7.32 (d, J = 8.3 Hz, 1H), 7.28 (d, J = 8.3 Hz, 1H), 7.20 
(d, J = 8.0 Hz, 1H), 6.93 (s, 1H), 6.57 (d, J = 5.6 Hz, 1H), 6.43–6.47 (m, 2H), 6.13 (d, J = 
7.5 Hz, 1H), 4.47 (d, J = 8.5 Hz, 1H), 2.02 (s, 3H), 1.98 (s, 3H), 1.85 (s, 3H), 1.82 (s, 3H); 
purity by HPLC = 97 %; ESI MS calcd for C41H33N6Ru [M]+ 711.18, found 711.3 [M]+; 
UV/Vis (CH3CN): λmax (ε) 490 nm (8400 mol−1dm3cm−1).
6 Rf=0.38 (0.1% KNO3, 5%H2O in MeCN); 1H NMR (CD3CN): δ 8.69 (d, J = 8.3 Hz, 1H), 
8.62 (d, J = 8.3 Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.23 (d, J = 8.8 Hz, 1H), 8.09–8.15 (m, 
3H), 8.00 (d, J = 7.9 Hz, 1H), 7.82–7.88 (m, 3H), 7.72 (d, J = 8.3 Hz, 1H), 7.36–7.43 (m, 
3H), 7.15 (t, J = 7.4 Hz, 1H), 6.93–7.00 (m, 3H), 6.72 (ddd, J = 8.8, 7.3, 0.9 Hz, 1H), 4.91 
(d, J = 8.5 Hz, 1H), 1.98 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H), 1.88 (s, 3H); purity by HPLC = 
97 %; ESI MS calcd for C40H33N7Ru [M]2+ 356.59; found 356.7 [M]2+; UV/Vis (CH3CN): 
λmax (ε) 455 nm (11800 mol−1dm3cm−1).
7 Rf=0.52 (0.1% KNO3, 5%H2O in MeCN); 1H NMR (CD3CN): δ 8.74 (d, J = 8.3 Hz, 1H), 
8.68 (d, J = 8.3 Hz, 1H), 8.35 (d, J = 8.3 Hz, 1H), 8.27 (d, J = 8.7 Hz, 1H), 8.23 (d, J = 8.3 
Hz, 1H), 8.13–8.20 (m, 3H), 7.94–7.98 (m, 2H), 7.86 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.4 
Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.40–7.46 (m, 3H), 7.16 (ddd, J = 8.0, 5.8, 1.5 Hz 1H), 
7.00–7.04 (m, 2H), 5.12 (d, J = 8.3 Hz, 1H), 2.11 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.90 (s, 
3H); purity by HPLC = 98 %; ESI MS calcd for C40H32N6ORu [M2+•PF6−]+ 859.13, 
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[M]2+ 357.09; found 859.3 [M2+•PF6−]+, 356.9 [M]2+; UV/Vis (CH3CN): λmax (ε) 445 nm 
(7700 mol−1dm3cm−1).
8 Rf=0.51 (0.1% KNO3, 5%H2O in MeCN);1H NMR (CD3CN): δ 8.72 (d, J = 8.3 Hz, 1H), 
8.67 (d, J = 8.3 Hz, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 8.4 
Hz, 1H), 8.16–8.20 (m, 2H), 8.08 (d, J = 8.8 Hz, 1H), 7.91–7.95 (m, 2H), 7.89 (d, J = 8.4 
Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.40 (d, 
J = 8.4 Hz, 1H), 7.34 (ddd, J = 8.8, 7.4, 1.0 Hz, 1H), 7.09–7.14 (m, 2H), 6.92 (ddd, J = 8.8, 
7.1, 1.2 Hz, 1H), 5.37 (d, J = 8.6 Hz, 1H), 2.10 (s, 3H), 2.01 (s, 3H), 1.85 (s, 3H), 1.84 (s, 
3H); purity by HPLC = 99 %; ESI MS calcd for C40H32N6RuS [M2+•PF6−]+ 875.11, 
[M]2+ 365.08; found 875.3 [M2+•PF6−]+, 365.1 [M]2+; UV/Vis (CH3CN): λmax (ε) 445 nm 
(8900 mol−1dm3cm−1).
General Preparation of Ru(bpy)2L Complexes
Ru(bpy)2Cl2•2H2O (120 mg, 0.23 mmol) and 2-(2-pyridyl)benzazole (0.27 mmol) were 
added to 6 mL of 50:50 EtOH:H2O in a 15 mL pressure tube. The mixture was heated at 
90 °C for 2 h, after which the orange solution was allowed to cool to room temperature. 
Addition of a saturated aq KPF6 solution resulted in precipitation of the complex, which was 
extracted into methylene chloride. Purification of the orange solid was carried out by flash 
chromatography (silica gel, loaded in 0.1% KNO3, 5% H2O in MeCN). The pure complex 
eluted at 0.2% KNO3, 10% H2O in MeCN, and the product fractions were concentrated 
under reduced pressure. A saturated aq solution of KPF6 was added, and the complex was 
extracted into CH2Cl2, followed by removal of the solvent under reduced pressure to give an 
orange solid.
9 Rf=0.60 (0.1% KNO3, 5%H2O in MeCN);1H NMR (CD3CN): δ 8.40–8.44 (m, 3H), 8.30 
(d, J = 8.2 Hz, 1H), 7.92–8.01 (m, 5H), 7.88 (td, J = 8.0, 1.5 Hz, 1H), 7.75–7.90 (m, 2H), 
7.69 (ddd, J = 8.2, 7.5, 1.6 Hz, 1H), 7.55 (ddd, J = 6.0, 1.6, 0.8 Hz, 1H), 7.46 (dt, J = 8.0, 1.0 
Hz, 1H), 7.31–7.35 (m, 3H), 7.19–7.27 (m, 3H), 6.89 (ddd, J = 8.0, 5.8, 1.6 Hz, 1H), 6.68 
(ddd, J = 8.0, 6.8, 0.8 Hz, 1H), 6.47 (ddd, J = 8.8, 6.8, 1.2 Hz, 1H), 5.38 (d, J = 7.5 Hz, 1H); 
purity by HPLC = 98 %; ESI MS calcd for C33H25N6Ru [M] + 607.12; found 607.1 [M]+; 
UV/Vis (CH3CN): λmax (ε) 480 nm (8600 mol−1dm3cm−1).
10 Rf=0.38 (0.1% KNO3, 5%H2O in MeCN);1H NMR (CD3CN): δ 8.51–8.54 (m, 3H), 8.47 
(d, J = 8.1 Hz, 1H), 8.44 (d, J = 8.1 Hz, 1H), 7.96–8.15 (m, 6H), 7.80–7.87 (m, 3H), 7.71–
7.75 (m, 2H), 7.47 (ddd, J = 8.0, 5.6, 1.3 Hz, 1H), 7.37–7.44 (m, 4H), 7.34 (ddd, J = 8.0, 5.6, 
1.2 Hz, 1H), 7.05 (ddd, J = 8.8, 7.4, 1.1 Hz, 1H), 5.82 (d, J = 8.3 Hz, 1H); purity by HPLC = 
99 %; ESI MS calcd for C32H25N7Ru [M]2+ 304.56; found 304.6 [M]2+; UV/Vis (CH3CN): 
λmax (ε) 455 nm (13100 mol−1dm3cm−1).
11 Rf=0.45 (0.1% KNO3, 5%H2O in MeCN);1H NMR (CD3CN): δ 8.51–8.54 (m, 3H), 8.48 
(d, J = 7.9 Hz, 1H), 8.45 (d, J = 8.2 Hz, 1H), 8.01–8.19 (m, 6H), 7.94 (d, J = 5.4 Hz, 1H), 
7.88 (d, J = 8.5 Hz, 1H), 7.77–7.82 (m, 3H), 7.61 (ddd, J = 8.8, 7.5, 1.1 Hz, 1H), 7.55 (ddd, J 
= 8.0, 5.6, 1.3 Hz, 1H), 7.42–7.49 (m, 3H), 7.39 (ddd, J = 8.0, 5.6, 1.2 Hz, 1H), 7.28 (ddd, J 
= 8.8, 7.6, 0.9 Hz, 1H), 5.96 (d, J = 8.2 Hz, 1H); purity by HPLC = 95 %; ESI MS calcd for 
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C32H25N6ORu [M]2+ 305.06; found 305.1 [M]2+; UV/Vis (CH3CN): λmax (ε) 450 nm 
(12600 mol−1dm3cm−1).
12 Rf=0.45 (0.1% KNO3, 5%H2O in MeCN);1H NMR (CD3CN): δ 8.51–8.54 (m, 4H), 8.44 
(d, J = 8.1 Hz, 1H), 8.20 (d, J = 8.1 Hz, 1H), 8.04–8.16 (m, 4H), 8.01 (td, J = 8.0, 1.4 Hz, 
1H), 7.92 (d, J = 5.8 Hz, 1H), 7.84 (d, J = 5.2 Hz, 1H), 7.74 (d, J = 5.7 Hz, 1H), 7.69 (d, J = 
5.5 Hz, 1H), 7.67 (d, J = 5.3 Hz, 1H), 7.57 (ddd, J = 8.4, 7.2, 1.0 Hz, 1H), 7.45–7.49 (m, 
2H), 7.37–7.42 (m, 2H), 7.35 (ddd, J = 8.0, 5.6, 1.2 Hz, 1H), 7.27 (ddd, J = 8.8, 7.3, 1.1 Hz, 
1H), 6.31 (d, J = 8.5 Hz, 1H); purity by HPLC = 98 %; ESI MS calcd for C32H24N6RuS 
[M2+•PF6−]+ 771.05, [M]2+ 313.04; found 771.2 [M2+•PF6−]+, 313.1 [M]2+; UV/Vis 
(CH3CN): λmax (ε) 445 nm (13100 mol−1dm3cm−1).
Counter ion exchange
Compounds 5–12 were converted to Cl− salts by dissolving 5–20 mg of product in 1–2 mL 
methanol. The dissolved product was loaded onto an Amberlite IRA-410 chloride ion 
exchange column, eluted with methanol, and the solvent was removed in vacuo.
Cytotoxicity Assay
HL60 cells were plated at 30,000 cell per well in Opti-MEM media with 1% FBS and pen-
strep in 96 well plates. Compounds were serially diluted in opti-MEM with 1% FBS and 
pen-strep in a 96 well plate and then added to the cells. They were then irradiated with 29.1 
J/cm2 light (>450 nm using the Indigo LED) for 1 minute or kept in the dark. The cells were 
incubated with the compounds for 72 h followed by the addition of resazurin. The plates 
were incubated for 3 h and then read on a SpectraFluor Plus plate reader with an excitation 
filter of 535 nm and emission of 595 nm.
DNA Gel Electrophoresis
Compounds were mixed with 40 μg/mL pUC19 plasmid DNA in 10 mM potassium 
phosphate buffer, pH 7.4. To determine the effect of light, samples were irradiated with a 
470 nm LED for a total light dose of 46.8 J/cm2. Samples were then incubated for 12 h at 
room temperature in the dark. Single- and double-strand DNA break controls were prepared, 
and the DNA samples were resolved on agarose gels, as described previously.[8a] In brief, 
samples were resolved on a 1% agarose gels prepared in tris-acetate buffer with 0.3 μg of 
plasmid/lane. The gels were stained with 0.5 μg/mL ethidium bromide in tris-acetate buffer 
at room temperature for 40 min, destained with tris-acetate buffer, and imaged on a 
ChemiDoc MP System (Bio-Rad).
Singlet Oxygen Assay
Compounds were serially diluted in 10 mM potassium phosphate buffer, pH 7.4, with ~5μM 
Singlet Oxygen Sensor Green reagent in 96 well plates. The plates were read on a 
SpectraFluor Plus plate reader with an excitation filter of 485 nm and emission of 535 nm in 
a dark and after 1h irradiation with a 470 nm LED for total light dose of 46.8 J/cm2.
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Cell Cycle Analysis
HL60 cells were plated in opti-MEM with 1% FBS at a density of 500,000 cells/ml in 6-well 
plates. The compounds were added and incubated with the cells from 0 to 12 h. For each 
time point the cells were transferred to FACS tubes, pelleted, washed with PBS, followed by 
the addition of cold 70% ethanol and incubated on ice for one hour to fix the cells. Cells 
were then centrifuged at 2000 rpm for 5 minutes, and resuspended in 1 ml PBS for each 
tube. The tubes were centrifuged at 2000 rpm for 5 minutes, the supernatant was aspirated 
and the cells were resuspended in 0.5 mL PI staining buffer (20 mg/mL PI in PBS, 0.2 
mg/mL RNAse, 0.1% TritonX-100) and incubated at room temperature for 30 minutes. 
Samples were run through the flow cytometer and data was analyzed with ModFit and 
FlowJo.
Crystallography
Single crystals of compounds 6–8 were grown from methylene chloride or acetone by vapor 
diffusion of diethyl ether. They were mounted in inert oil and transferred to the cold gas 
stream of the diffractometer. X-ray diffraction data were collected at 90.0(2) K on either a 
Nonius kappaCCD diffractometer using MoKα X-rays or on a Bruker-Nonius X8 Proteum 
diffractometer with graded-multilayer focused CuKα X-rays. Raw data were integrated, 
scaled, merged and corrected for Lorentz-polarization effects using either the HKL-SMN 
package[19] or the APEX2 package.[20] Corrections for absorption were applied using 
SADABS[21] and XABS2.[22] The structures were solved by SHELXT,[23] and refined 
against F2 by weighted full-matrix least-squares using SHELXL-2014.[24] For compound 8 
the SQUEEZE routine[25] was used to treat disordered solvent. Hydrogen atoms were placed 
at calculated positions and refined using a riding model. Non-hydrogen atoms were refined 
with anisotropic displacement parameters. Structures were checked using check CIF tools in 
Platon[26] and by an R-tensor.[27] Crystal data and relevant details of the structure 
determinations are summarized below and selected geometrical parameters are given in 
Table 1.
Crystal data (6)—C41H35Cl2F12N7P2Ru, Mr = 1087.67, Monoclinic, P21/c, a = 
12.3286(2) Å, b = 18.7316(3)Å, c = 18.1692(3) Å, β = 94.943(1)°, V = 4180.29(12)Å3, Z = 
4, ρ = 1.728 mg m−3, μ = 5.802 mm−1, F(000) = 2184, crystal size = 0.300×0.120×0.060 
mm, θ(max) = 68.373°, 56392 reflections collected, 7596 unique reflections (Rint = 0.0433), 
GOF = 1.065, R1 = 0.0408 and wR2 = 0.0933 [I > 2σ(I)], R1 = 0.0436 and wR2 = 0.0949 (all 
indices), largest difference peak/hole = 1.531/−1.465 eÅ−3.
Crystal data (7)—C48.29H50.15F12N6O3.50P2Ru, Mr = 1161.55, Monoclinic, C2/c, a = 
23.0734(5) Å, b = 19.9646(5) Å, c = 22.6098(5) Å, β = 108.547(1)°, V = 9874.3(4) Å3, Z = 
8, ρ = 1.563 mg m−3, μ = 4.028 mm−1, F(000) = 4735, crystal size = 0.230×0.180×0.030 
mm, θ(max) = 68.355°, 60921 reflections collected, 8945 unique reflections (Rint = 0.0643), 
GOF = 1.036, R1 = 0.0409 and wR2 = 0.0985 [I > 2σ(I)], R1 = 0.0561 and wR2 = 0.1067 (all 
indices), largest difference peak/hole = 0.631/−0.544 eÅ−3.
Crystal data (8)—C89H82F24N12O3P4Ru2S2, Mr = 2213.80, Triclinic, P-1, a = 14.2840(2) 
Å, b = 17.5165(2)Å, c = 20.0585(3)Å, α = 91.5547(8)°, β = 90.7709(8)°, γ = 
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110.9785(7)°, V = 4682.91(11)Å3, Z = 2, ρ = 1.570 mg m−3, μ = 0.539 mm−1, F(000) = 
2240, crystal size = 0.320×0.280×0.270 mm, θ(max) = 27.509°, 136315 reflections 
collected, 21482 unique reflections (Rint = 0.0402), GOF = 1.054, R1 = 0.0445 and wR2 = 
0.1153 [I > 2σ(I)], R1 = 0.0688 and wR2 = 0.1297 (all indices), largest difference peak/hole 
= 1.247/−0.749 eÅ−3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Ellipsoid plot of ruthenium complexes A) (Δ)-6, B) (Δ)-7, C) (Λ)-8 at 50% probability with 
H atoms omitted for clarity. Right column: side views highlighting the distortion of the 
dmphen ligand. The black dashed lined indicates the normal plane and the angle between red 
and black dash line represents the ligand bend. Note: for 8 only one cation of the asymmetric 
unit is shown.
Havrylyuk et al. Page 13
Eur J Inorg Chem. Author manuscript; available in PMC 2018 March 27.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 2. 
A) Photoejection of 7 (30 μM) in water for 0–240 min irradiation followed by UV/Vis 
absorption; red = initial, blue = final. B) The photoejection kinetics for 7; reaction was 
complete in less than 5 min. Determination of photoejection products by HPLC: C) 
Absorption profile of 7 (black, retention time = 10.56 min) and the photochemical product 
(blue, retention time = 9.55 min); note that the presence of CH3CN changes the absorption 
profile; see Figure S28). D) Photoejection reaction scheme for 6–8, showing the 
photochemical products. E) HPLC chromatogram of 7 before (black) and after irradiation 
for 1 min with the Indigo LED (blue), in comparison with started ligands: dmphen (red) and 
pbo (green). The same light dose was used in the cell studies.
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Figure 3. 
Cytotoxicity dose responses of ruthenium complexes and parent ligand on HL60 cells: A) 2 
and 6; B) 10. Dark conditions (circles, blue line); irradiated samples, 1 min >450 nm light 
using the Indigo LED (29.1 J/cm2; squares, red line); ligand 2 (triangles, green line). (n = 3).
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Figure 4. 
SAR Analysis for Antitumor Ru(II) Complexes with 2-(2-Pyridyl)Benzazole Ligands
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Figure 5. 
Agarose gel electrophoresis of 40 μg/mL pUC19 plasmid (10 mM phosphate buffer, pH 7.5) 
with light-activated Ru(II) compounds. Dose response profiles: (A) 6; (B) 8; (C) 10; (D) 12; 
Lanes 1 and 12, DNA molecular weight standard; lane 2, linear pUC19; lane 3, relaxed 
circle (Cu(phen)2 reaction with pUC19); lanes 4−11, 0, 7.8, 15.6, 31.25, 62.5, 125, 250, and 
500 μM compound. E) Singlet oxygen generation dose responses of ruthenium complexes: 6 
(circles, orange line); 8 (squares, red line); 10 (circles, blue line); and 12 (squares, green 
line). (n = 2). The data is shown as a ratio of the emission of the sensor after irradiation with 
the compound vs. without irradiation. The slight downward curve for 8 suggests this 
compound quenches singlet oxygen at high doses.
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Scheme 1. 
Synthesis of Ru(II) complexes with bioisosteric 2-(2-pyridyl)benzazole ligands. Reagents, 
conditions and yields: (a) Ru(dmphen)2Cl2 (1.0 eq), ethylene glycol, 100–120 °C for 2 h (5–
8), 20–30%; (b) Ru(bpy)2Cl2 (1.0 eq), ethanol-water (1:1), 90 °C for 2 h (9–12), 45–95%.
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Table 1
Selected bond lengths (Å), bond angles (°) and torsion angles (°) of 6–8.
6 7 8
Bond Lengths (Å)
Ru-N1 2.114(3) 2.114(3) 2.114(2)
Ru-N2 2.097(3) 2.103(3) 2.102(2)
Ru-N3 2.100(3) 2.090(3) 2.097(2)
Ru-N4 2.120(3) 2.105(3) 2.108(2)
Ru-N5 2.109(3) 2.106(3) 2.097(2)
Ru-N6 2.099(3) 2.112(3) 2.112(2)
Bond Angles (°)
N1-Ru-N2 79.45(11) 79.73(10) 79.06(9)
N1-Ru-N3 100.6(1) 100.96(11) 101.40(9)
N1-Ru-N4 178.35(11) 178.86(11) 177.52(9)
N1-Ru-N5 95.9(1) 95.99(10) 96.07(9)
N1-Ru-N6 81.86(10) 80.24(11) 82.05(9)
N2-Ru-N3 94.57(10) 94.56(10) 93.35(9)
N2-Ru-N4 102.1(1) 100.78(10) 103.19(9)
N2-Ru-N5 170.3(1) 171.59(10) 171.30(9)
N2-Ru-N6 92.78(10) 94.05(10) 94.03(9)
N3-Ru-N4 79.88(11) 80.04(11) 79.62(9)
N3-Ru-N5 94.66(10) 93.36(10) 94.69(9)
N3-Ru-N6 172.56(10) 171.39(10) 172.34(9)
N4-Ru-N5 82.49(10) 83.38(10) 81.57(9)
N4-Ru-N6 97.46(10) 98.69(10) 96.67(9)
N5-Ru-N6 78.06(10) 78.02(10) 78.07(10)
Torsion Angles (°)
N1-C6-C7-N2 2.1(4) 1.2(5) −2.2(4)
Ru-N1-C2-C3 −167.4(3) −167.1(3) 163.2(2)
Ru-N2-C11-C10 164.0(2) 165.9(3) −162.8(2)
N3-C20-C21-N4 1.8(5) 2.0(4) −4.0(4)
Ru-N3-C16-C17 169.4(3) 168.7(3) −171.0(2)
Ru-N4-C25-C24 −165.6(2) −167.8(2) 162.3(2)
N5-C33-C34-N6 1.8(4) 3.0(5) −2.3(4)
Ru-N5-C29-C30 176.0(3) 175.3(3) −177.4(2)
L1 bend a 22.6 22.6 22.7
L2 bend b 21.4 19.5 21.6
a
L1 bend = average angle (N3-Ru-C13/C14) – 90°; L1 – dmphen where L is N1 and N2
b
L2 bend = average angle (N2-Ru-C27/C28) – 90°; L2 – dmphen where L is N3 and N4
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Table 2
Photophysical and photochemical properties for 5–12 for various reaction conditions.
Compound
λmax (nm) t1/2 (min)
water Opti-MEM water Opti-MEM
5 475 475 47.3±2.80 n.r.*
6 455 455 1.17±0.08 10.38±0.33
7 450 450 1.03±0.09 1.42±0.04
8 440 440 0.34±0.04 0.66±0.002
9 490 490 66.02±13.11 66.11±5.95
10 455 435 n.r. n.r.
11 450 450 n.r. n.r.
12 445 450 n.r. n.r.
*
n.r. = no reaction
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